ID   PLCG1_RAT               Reviewed;        1290 AA.
AC   P10686;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   22-JUL-2015, entry version 174.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1;
DE            EC=3.1.4.11;
DE   AltName: Full=Phosphoinositide phospholipase C-gamma-1;
DE   AltName: Full=Phospholipase C-gamma-1;
DE            Short=PLC-gamma-1;
GN   Name=Plcg1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2840660; DOI=10.1073/pnas.85.15.5419;
RA   Suh P.-G., Ryu S.H., Moon K.H., Suh H.W., Rhee S.G.;
RT   "Inositol phospholipid-specific phospholipase C: complete cDNA and
RT   protein sequences and sequence homology to tyrosine kinase-related
RT   oncogene products.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:5419-5423(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-29.
RX   PubMed=8392838; DOI=10.1006/bbrc.1993.1818;
RA   Lee S.J., Ryu S.H., Suh P.G.;
RT   "Promoter region of the rat phospholipase C-gamma 1 gene.";
RL   Biochem. Biophys. Res. Commun. 194:294-300(1993).
RN   [3]
RP   INTERACTION WITH FGFR4, AND PHOSPHORYLATION.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G.,
RA   Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [4]
RP   INTERACTION WITH AGAP2, AND MUTAGENESIS OF PRO-842.
RX   PubMed=11823862; DOI=10.1038/415541a;
RA   Ye K., Aghdasi B., Luo H.R., Moriarity J.L., Wu F.Y., Hong J.J.,
RA   Hurt K.J., Bae S.S., Suh P.-G., Snyder S.H.;
RT   "Phospholipase C gamma 1 is a physiological guanine nucleotide
RT   exchange factor for the nuclear GTPase PIKE.";
RL   Nature 415:541-544(2002).
RN   [5]
RP   STRUCTURE BY NMR OF 489-553 AND 663-759.
RX   PubMed=16500902; DOI=10.1074/jbc.M600336200;
RA   Wen W., Yan J., Zhang M.;
RT   "Structural characterization of the split pleckstrin homology domain
RT   in phospholipase C-gamma1 and its interaction with TRPC3.";
RL   J. Biol. Chem. 281:12060-12068(2006).
CC   -!- FUNCTION: Mediates the production of the second messenger
CC       molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate
CC       (IP3). Plays an important role in the regulation of intracellular
CC       signaling cascades. Becomes activated in response to ligand-
CC       mediated activation of receptor-type tyrosine kinases, such as
CC       PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in
CC       actin reorganization and cell migration (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate +
CC       diacylglycerol.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- ENZYME REGULATION: Activated by phosphorylation on tyrosine
CC       residues. {ECO:0000250}.
CC   -!- SUBUNIT: Interacts (via SH2 domain) with FGFR1, FGFR2, FGFR3 and
CC       FGFR4 (phosphorylated). Interacts (via SH3 domain) with AGAP2.
CC       Interacts with LAT (phosphorylated) upon TCR activation. Interacts
CC       (via SH3 domain) with the Pro-rich domain of TNK1. Associates with
CC       BLNK, VAV1, GRB2 and NCK1 in a B-cell antigen receptor-dependent
CC       fashion. Interacts with CBLB in activated T-cells; which inhibits
CC       phosphorylation. Interacts with SHB. Interacts (via SH3 domain)
CC       with the Arg/Gly-rich-flanked Pro-rich domains of KHDRBS1/SAM68.
CC       This interaction is selectively regulated by arginine methylation
CC       of KHDRBS1/SAM68. Interacts with INPP5D/SHIP1, THEMIS and CLNK (By
CC       similarity). Interacts with RALGPS1. Interacts (via the SH2
CC       domains) with VIL1 (phosphorylated at C-terminus tyrosine
CC       phosphorylation sites). Interacts (via SH2 domain) with RET (By
CC       similarity). Interacts with FLT1 (tyrosine-phosphorylated).
CC       Interacts with AXL, FLT4 and KIT. Interacts (via SH2 domain) with
CC       PDGFRA and PDGFRB (tyrosine phosphorylated) (By similarity).
CC       Interacts with PIP5K1C (By similarity). Interacts with NTRK1 and
CC       NTRK2 (phosphorylated upon ligand-binding) (By similarity).
CC       Interacts with SYK; activates PLCG1 (By similarity). Interacts
CC       with TESPA1 (By similarity). Interacts with GRB2, LAT and THEMIS
CC       upon TCR activation in thymocytes (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P11362:FGFR1 (xeno); NbExp=4; IntAct=EBI-520788, EBI-1028277;
CC       Q04589:Fgfr1; NbExp=2; IntAct=EBI-520788, EBI-2480918;
CC       Q62120:Jak2 (xeno); NbExp=3; IntAct=EBI-520788, EBI-646604;
CC       P18031:PTPN1 (xeno); NbExp=4; IntAct=EBI-520788, EBI-968788;
CC       Q13507:TRPC3 (xeno); NbExp=2; IntAct=EBI-520788, EBI-520807;
CC   -!- SUBCELLULAR LOCATION: Cell projection, lamellipodium
CC       {ECO:0000250}. Cell projection, ruffle {ECO:0000250}. Note=Rapidly
CC       redistributed to ruffles and lamellipodia structures in response
CC       to epidermal growth factor (EGF) treatment. {ECO:0000250}.
CC   -!- DOMAIN: The SH3 domain mediates interaction with CLNK and RALGPS1.
CC       {ECO:0000250}.
CC   -!- PTM: May be dephosphorylated by PTPRJ (By similarity). Tyrosine
CC       phosphorylated by activated FGFR1, FGFR2, FGFR3 and FGFR4. The
CC       receptor-mediated activation of PLCG1 involves its phosphorylation
CC       by tyrosine kinases in response to ligation of a variety of growth
CC       factor receptors and immune system receptors. For instance, SYK
CC       phosphorylates and activates PLCG1 in response to ligation of the
CC       B-cell receptor. Tyrosine phosphorylated in response to signaling
CC       via activated FLT1, FLT3, KIT and PDGFRB. Phosphorylated by ITK
CC       and TXK on Tyr-783 upon TCR activation in T-cells (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by CBLB in activated T-cells. {ECO:0000250}.
CC   -!- SIMILARITY: Contains 1 C2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00041}.
CC   -!- SIMILARITY: Contains 1 EF-hand domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00448}.
CC   -!- SIMILARITY: Contains 2 PH domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00145}.
CC   -!- SIMILARITY: Contains 1 PI-PLC X-box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00270}.
CC   -!- SIMILARITY: Contains 1 PI-PLC Y-box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00271}.
CC   -!- SIMILARITY: Contains 2 SH2 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SH3 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00192}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03806; AAA41921.1; -; mRNA.
DR   EMBL; L14476; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; A31317; A31317.
DR   RefSeq; NP_037319.1; NM_013187.1.
DR   UniGene; Rn.11243; -.
DR   PDB; 1Y0M; X-ray; 1.20 A; A=791-851.
DR   PDB; 1YWO; X-ray; 1.81 A; A=790-851.
DR   PDB; 1YWP; X-ray; 1.60 A; A=790-851.
DR   PDB; 2FJL; NMR; -; A=489-547, A=851-933.
DR   PDB; 3GQI; X-ray; 2.50 A; B=545-770.
DR   PDB; 4K44; X-ray; 1.70 A; A/B=664-766.
DR   PDB; 4K45; X-ray; 1.50 A; A=664-766, B=770-787.
DR   PDBsum; 1Y0M; -.
DR   PDBsum; 1YWO; -.
DR   PDBsum; 1YWP; -.
DR   PDBsum; 2FJL; -.
DR   PDBsum; 3GQI; -.
DR   PDBsum; 4K44; -.
DR   PDBsum; 4K45; -.
DR   ProteinModelPortal; P10686; -.
DR   SMR; P10686; 320-454, 489-658, 663-759, 795-848, 851-933.
DR   BioGrid; 247766; 1.
DR   DIP; DIP-2863N; -.
DR   IntAct; P10686; 10.
DR   MINT; MINT-231720; -.
DR   STRING; 10116.ENSRNOP00000022276; -.
DR   BindingDB; P10686; -.
DR   ChEMBL; CHEMBL5188; -.
DR   PhosphoSite; P10686; -.
DR   PaxDb; P10686; -.
DR   PRIDE; P10686; -.
DR   GeneID; 25738; -.
DR   KEGG; rno:25738; -.
DR   UCSC; RGD:3347; rat.
DR   CTD; 5335; -.
DR   RGD; 3347; Plcg1.
DR   eggNOG; NOG268751; -.
DR   HOGENOM; HOG000230864; -.
DR   HOVERGEN; HBG053611; -.
DR   InParanoid; P10686; -.
DR   KO; K01116; -.
DR   PhylomeDB; P10686; -.
DR   BRENDA; 3.1.4.11; 5301.
DR   Reactome; REACT_296726; VEGFR2 mediated cell proliferation.
DR   Reactome; REACT_317818; Role of phospholipids in phagocytosis.
DR   Reactome; REACT_322024; PLC-gamma1 signalling.
DR   Reactome; REACT_325357; DAG and IP3 signaling.
DR   Reactome; REACT_339273; Role of second messengers in netrin-1 signaling.
DR   EvolutionaryTrace; P10686; -.
DR   NextBio; 607883; -.
DR   PMAP-CutDB; P10686; -.
DR   PRO; PR:P10686; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevisible; P10686; RN.
DR   GO; GO:0008180; C:COP9 signalosome; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:RGD.
DR   GO; GO:0030027; C:lamellipodium; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001726; C:ruffle; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:RGD.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:RGD.
DR   GO; GO:0004871; F:signal transducer activity; IEA:UniProtKB-KW.
DR   GO; GO:0006816; P:calcium ion transport; IMP:RGD.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0032959; P:inositol trisphosphate biosynthetic process; IMP:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:RGD.
DR   GO; GO:0009306; P:protein secretion; IMP:RGD.
DR   GO; GO:1901339; P:regulation of store-operated calcium channel activity; IMP:RGD.
DR   GO; GO:0009629; P:response to gravity; IEP:RGD.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0043278; P:response to morphine; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0007165; P:signal transduction; TAS:RGD.
DR   Gene3D; 1.10.238.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 3.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 2.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR011993; PH-like_dom.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR016279; PLC-gamma.
DR   InterPro; IPR028380; PLC-gamma1.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR015359; PLipase_C_EF-hand-like.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF52; PTHR10336:SF52; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF09279; EF-hand_like; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PIRSF; PIRSF000952; PLC-gamma; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 3.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF51695; SSF51695; 2.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Calcium; Cell projection;
KW   Complete proteome; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Metal-binding; Phosphoprotein; Reference proteome; Repeat; SH2 domain;
KW   SH3 domain; Transducer; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P19174}.
FT   CHAIN         2   1290       1-phosphatidylinositol 4,5-bisphosphate
FT                                phosphodiesterase gamma-1.
FT                                /FTId=PRO_0000088500.
FT   DOMAIN       27    142       PH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      152    187       EF-hand. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      320    464       PI-PLC X-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00270}.
FT   DOMAIN      489    523       PH 2; first part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      550    657       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      668    756       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      791    851       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      895    931       PH 2; second part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      953   1070       PI-PLC Y-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00271}.
FT   DOMAIN     1075   1177       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   CA_BIND     165    176       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   ACT_SITE    335    335       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   ACT_SITE    380    380       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P19174}.
FT   MOD_RES     506    506       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62077}.
FT   MOD_RES     771    771       Phosphotyrosine; by SYK. {ECO:0000250}.
FT   MOD_RES     775    775       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P19174}.
FT   MOD_RES     783    783       Phosphotyrosine; by ITK, SYK and TXK.
FT                                {ECO:0000250}.
FT   MOD_RES     977    977       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62077}.
FT   MOD_RES    1221   1221       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P19174}.
FT   MOD_RES    1248   1248       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P19174}.
FT   MOD_RES    1253   1253       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P08487}.
FT   MUTAGEN     842    842       P->L: Inhibits interaction with AGAP2.
FT                                {ECO:0000269|PubMed:11823862}.
FT   STRAND      491    499       {ECO:0000244|PDB:2FJL}.
FT   TURN        500    503       {ECO:0000244|PDB:2FJL}.
FT   STRAND      504    513       {ECO:0000244|PDB:2FJL}.
FT   STRAND      516    519       {ECO:0000244|PDB:2FJL}.
FT   STRAND      551    553       {ECO:0000244|PDB:3GQI}.
FT   HELIX       556    558       {ECO:0000244|PDB:3GQI}.
FT   HELIX       561    576       {ECO:0000244|PDB:3GQI}.
FT   STRAND      583    587       {ECO:0000244|PDB:3GQI}.
FT   STRAND      589    591       {ECO:0000244|PDB:3GQI}.
FT   STRAND      594    600       {ECO:0000244|PDB:3GQI}.
FT   STRAND      605    613       {ECO:0000244|PDB:3GQI}.
FT   STRAND      616    618       {ECO:0000244|PDB:3GQI}.
FT   STRAND      620    624       {ECO:0000244|PDB:3GQI}.
FT   STRAND      627    631       {ECO:0000244|PDB:3GQI}.
FT   HELIX       632    641       {ECO:0000244|PDB:3GQI}.
FT   HELIX       665    668       {ECO:0000244|PDB:4K45}.
FT   STRAND      669    672       {ECO:0000244|PDB:4K45}.
FT   HELIX       675    682       {ECO:0000244|PDB:4K45}.
FT   STRAND      690    695       {ECO:0000244|PDB:4K45}.
FT   STRAND      701    708       {ECO:0000244|PDB:4K45}.
FT   STRAND      711    720       {ECO:0000244|PDB:4K45}.
FT   STRAND      723    726       {ECO:0000244|PDB:4K45}.
FT   STRAND      729    733       {ECO:0000244|PDB:4K45}.
FT   HELIX       734    743       {ECO:0000244|PDB:4K45}.
FT   HELIX       758    762       {ECO:0000244|PDB:4K45}.
FT   STRAND      796    800       {ECO:0000244|PDB:1Y0M}.
FT   STRAND      817    822       {ECO:0000244|PDB:1Y0M}.
FT   STRAND      825    833       {ECO:0000244|PDB:1Y0M}.
FT   STRAND      836    842       {ECO:0000244|PDB:1Y0M}.
FT   HELIX       843    845       {ECO:0000244|PDB:1Y0M}.
FT   STRAND      846    848       {ECO:0000244|PDB:1Y0M}.
FT   STRAND      860    862       {ECO:0000244|PDB:2FJL}.
FT   TURN        864    870       {ECO:0000244|PDB:2FJL}.
FT   STRAND      874    876       {ECO:0000244|PDB:2FJL}.
FT   STRAND      882    886       {ECO:0000244|PDB:2FJL}.
FT   STRAND      890    892       {ECO:0000244|PDB:2FJL}.
FT   STRAND      896    900       {ECO:0000244|PDB:2FJL}.
FT   STRAND      904    906       {ECO:0000244|PDB:2FJL}.
FT   STRAND      909    912       {ECO:0000244|PDB:2FJL}.
FT   HELIX       916    930       {ECO:0000244|PDB:2FJL}.
SQ   SEQUENCE   1290 AA;  148548 MW;  BB3240C27972CE3B CRC64;
     MAGVGTPCAN GCGPSAPSEA EVLHLCRSLE VGTVMTLFYS KKSQRPERKT FQVKLETRQI
     TWSRGADKIE GSIDIREIKE IRPGKTSRDF DRYQEDPAFR PDQSHCFVIL YGMEFRLKTL
     SLQATSEDEV NMWIKGLTWL MEDTLQAATP LQIERWLRKQ FYSVDRNRED RISAKDLKNM
     LSQVNYRVPN MRFLRERLTD FEQRSGDITY GQFAQLYRSL MYSAQKTMDL PFLETNTLRT
     GERPELCQVS LSEFQQFLLE YQGELWAVDR LQVQEFMLSF LRDPLREIEE PYFFLDELVT
     FLFSKENSVW NSQLDAVCPE TMNNPLSHYW ISSSHNTYLT GDQFSSESSL EAYARCLRMG
     CRCIELDCWD GPDGMPVIYH GHTLTTKIKF SDVLHTIKEH AFVASEYPVI LSIEDHCSIA
     QQRNMAQHFR KVLGDTLLTK PVDIAADGLP SPNQLKRKIL IKHKKLAEGS AYEEVPTSVM
     YSENDISNSI KNGILYLEDP VNHEWYPHYF VLTSSKIYYS EETSSDQGNE DEEEPKEASG
     STELHSSEKW FHGKLGAGRD GRHIAERLLT EYCIETGAPD GSFLVRESET FVGDYTLSFW
     RNGKVQHCRI HSRQDAGTPK FFLTDNLVFD SLYDLITHYQ QVPLRCNEFE MRLSEPVPQT
     NAHESKEWYH ASLTRAQAEH MLMRVPRDGA FLVRKRNEPN SYAISFRAEG KIKHCRVQQE
     GQTVMLGNSE FDSLVDLISY YEKHPLYRKM KLRYPINEEA LEKIGTAEPD YGALYEGRNP
     GFYVEANPMP TFKCAVKALF DYKAQREDEL TFTKSAIIQN VEKQDGGWWR GDYGGKKQLW
     FPSNYVEEMI NPAILEPERE HLDENSPLGD LLRGVLDVPA CQIAIRPEGK NNRLFVFSIS
     MPSVAQWSLD VAADSQEELQ DWVKKIREVA QTADARLTEG KMMERRKKIA LELSELVVYC
     RPVPFDEEKI GTERACYRDM SSFPETKAEK YVNKAKGKKF LQYNRLQLSR IYPKGQRLDS
     SNYDPLPMWI CGSQLVALNF QTPDKPMQMN QALFMAGGHC GYVLQPSTMR DEAFDPFDKS
     SLRGLEPCVI CIEVLGARHL PKNGRGIVCP FVEIEVAGAE YDSTKQKTEF VVDNGLNPVW
     PAKPFHFQIS NPEFAFLRFV VYEEDMFSDQ NFLAQATFPV KGLKTGYRAV PLKNNYSEDL
     ELASLLIKID IFPAKENGDL SPFSGTSLRE RASDASSQLF HVRAREGSFE ARYQQPFEDF
     RISQEHLADH FDSRERRAPR RTRVNGDNRL
//
